Cooley advised FibroGen on its $120 million shelf takedown of 5,228,750 shares of common stock. FibroGen, which is headquartered in San Francisco and trades on The…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
